non-alcoholic steatohepatitispharmacotherapyNon゛lcoholic steatohepatitis (NASH) is a result of inflammation and hepatocyte injury in the presence of hepatic steatosis which can progress to cirrhosis. NASH is the most rapidly growing aetiology for liver failure and indication for liver transplantation in ...
In recent years, there has been an increasing number of clinical trials for the treatment of nonalcoholic steatohepatitis (NASH). People living with human immunodeficiency virus (PLWH) are commonly excluded from these studies, usually due to concerns over drug–drug interactions associated with ...
Study Points to New Biomarker for Nonalcoholic Steatohepatitis Diagnosis in Children With Nonalcoholic Fatty Liver DiseaseStudy Points to New Biomarker for Nonalcoholic Steatohepatitis Diagnosis in Children With Nonalcoholic Fatty Liver Diseasedoi:10.1053/j.gastro.2007.07.040Les...
Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review. Pharm Res. 2022;39(6):1233–48. Article CAS PubMed PubMed Central Google Scholar Li Z, et al. Modeling digestion, ...
Additionally, with the availability of better drugs and more treatment options for managing liver disorders related hepatotrophic viruses, the proportion and burden of alcoholic liver disease has grown, and is likely to increase in the coming years. Alcoholic hepatitis (AH) related hospital admissions...
Non-alcoholic steatohepatitis: new insights from OMICS studies. Non- alcoholic steatohepatitis: new insights from OMICS studies. Curr Pharm Biotechnol 2012;13:726-35.Martel, C.; Esposti, D.D.; Bouchet, A.; ... C Martel,DD Esposti,A Bouchet,... - 《Curr Pharm Biotechnol》 被引量: 65...
Metabolic diseases, such as obesity, diabetes mellitus, and non-alcoholic fatty liver disease (NAFLD), are abnormal conditions that result from disturbances of metabolism. With the improvement of living conditions, the morbidity and mortality rates of metabolic diseases are steadily rising, posing a ...
Silymarin in non-alcoholic steatohepatitis – a new kid on the block ? When the kidneys, liver, heart or lungs are incurably diseased, an organ transplant is often the last hope. But despite the many advances in modern medicine, the risks are still high – and the primary goal of doctors...
Nonalcoholic steatohepatitis (NASH), characterized by liver steatosis, inflammation and injury, has emerged as one of major causes for end-stage liver disease like hepatocellular carcinoma. However, what drives its progression? Ad More than twenty years ago, a "two-hit" theory was proposed to exp...
NAFLD is a worldwide threat. In the United States, 30 to 40 percent of adults are estimated to be affected, with about 20 percent of these patients having a more advanced stage called non-alcoholic steatohepatitis, or NASH, which is marked by liver inflammation and may progress to advanced ...